5AM Venture Management LLC acquired a new stake in shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 476,200 shares of the company's stock, valued at approximately $5,228,676. Silence Therapeutics makes up 0.0% of 5AM Venture Management LLC's investment portfolio, making the stock its 16th largest holding. 5AM Venture Management LLC owned approximately 1.01% of Silence Therapeutics at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. ADAR1 Capital Management LLC boosted its stake in Silence Therapeutics by 628.2% in the first quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company's stock valued at $907,000 after acquiring an additional 148,514 shares during the last quarter. Seven Fleet Capital Management LP bought a new position in Silence Therapeutics in the fourth quarter valued at approximately $897,000. Ishara Investments LP bought a new stake in shares of Silence Therapeutics in the 4th quarter valued at about $1,459,000. Nantahala Capital Management LLC increased its stake in shares of Silence Therapeutics by 48.0% in the 4th quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company's stock valued at $9,378,000 after acquiring an additional 500,000 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Silence Therapeutics by 87.1% in the 4th quarter. Marshall Wace LLP now owns 155,680 shares of the company's stock valued at $947,000 after acquiring an additional 72,461 shares during the last quarter. Hedge funds and other institutional investors own 98.73% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on SLN. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Silence Therapeutics in a research note on Friday, July 17th. Cantor Fitzgerald assumed coverage on Silence Therapeutics in a research note on Wednesday, June 24th. They issued an "overweight" rating for the company. Morgan Stanley lifted their price target on shares of Silence Therapeutics from $25.00 to $32.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 11th. Finally, HC Wainwright reissued a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $53.50.
Check Out Our Latest Research Report on SLN
Silence Therapeutics Stock Down 0.2%
Shares of NASDAQ SLN opened at $13.42 on Friday. The company's fifty day moving average is $11.49 and its 200-day moving average is $8.08. The stock has a market cap of $808.02 million, a price-to-earnings ratio of -10.48 and a beta of 1.39. Silence Therapeutics PLC Sponsored ADR has a twelve month low of $4.19 and a twelve month high of $17.58.
Silence Therapeutics (NASDAQ:SLN - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. On average, research analysts anticipate that Silence Therapeutics PLC Sponsored ADR will post -1.03 EPS for the current fiscal year.
About Silence Therapeutics
(
Free Report)
Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence's technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.
The company's lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.
Featured Stories
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Silence Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silence Therapeutics wasn't on the list.
While Silence Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
